Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
NCT03936270
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
+55 51 3384 5334
1. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study;
2. Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
3. 18 years of age or older;
4. Patient agrees not to participate in another interventional study while on treatment;
5. Histologically diagnosed endometrioid or high-grade serous ovarian cancer, estrogen (ER) and/or progesterone (PR) receptor positive (defined as > 10% by immunohistochemistry);
6. Patients must have completed 2 previous courses of chemotherapy:
1. The penultimate regimen must be a platinum-based chemotherapy course prior to enrolment on the study:
2. For the last chemotherapy course prior to enrolment on the study:
- There is no pre-specified regimen;
- It may contain a Platinum salt or not (depending upon Platinum sensitivity), at discretion of treating Physician;
- Patients must have demonstrated disease progression by RECIST v1.1 to the last treatment
- Patients must be treated on the study within 8 weeks of completion of their final dose of second line regimen;
7. Formalin fixed, paraffin embedded tumor sample from the primary tumor must be available for central testing;
8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
9. Adequate bone marrow function at screening:
- Absolute Neutrophil Count (ANC) ≥ 1,500/mm³ (≥ 1.5x109/L)
- Platelets ≥ 100,000/mm³ or ≥ 100 x 109/L
- Hemoglobin ≥ 9.0 g/dL;
10. Adequate liver function at screening:
- Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (≤ 3.0 x ULN if Gilbert Syndrome)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN (≤ 5.0 x ULN if there is tumor involvement in the liver)
- Alkaline phosphatase ≤ 2.5 x ULN (≤ 5.0 x ULN if there is tumor involvement in the liver);
11. Adequate renal function at screening:
- Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50mL/min;
12. Evidence of non-childbearing potential:
- Postmenopausal (defined as at least 1 year without any menses) prior to screening, or
- Radiation-induced oophorectomy with last menses >1 year ago, or
- Surgical sterilisation (bilateral oophorectomy or hysterectomy).
1. Patients with a known hypersensitivity to Palbociclib or Letrozole or any of the
excipients of the product;
2. Previous treatment with CDK inhibitors or endocrine therapy;
3. Persistent toxicities (grade 2 or greater) caused by previous cancer therapy
(excluding alopecia);
4. Patients with second primary cancer, except: adequately treated non-melanoma skin
cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ
(DCIS), stage 1 grade 1 endometrial carcinoma curatively treated with no evidence of
disease for 3 years;
5. Patients receiving any chemotherapy, radiotherapy, within 3 weeks from the last dose
prior to study entry;
6. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence
of brain metastases is not required;
7. Major surgical procedure within 3 weeks prior to study randomization, or one is
planned during the course of the study;
8. Patients considered poor medical risk due to a serious, uncontrolled medical disorder,
non-malignant systemic disease or active, uncontrolled infection. Examples include,
but are not limited to, uncontrolled ventricular arrhythmia, recent (within 6 months)
myocardial infarction, cerebrovascular accident, gastrointestinal bleeding, or any
psychiatric disorder that prohibits obtaining informed consent;
9. Patients that have difficulty taking oral medication or any digestive tract
dysfunction or inflammatory bowel disease that would interfere with the intestinal
absorption of drugs (eg, partial bowel obstruction or malabsorption);
10. Patients have received potent inhibitors or inducers of CYP3A4 within 7 days prior to
randomization;
11. Pregnant or breast feeding women;
12. Patient has a known history of positive test for human immunodeficiency virus (HIV);
13. Patients with known hepatic disease (ie, Hepatitis B or C);
14. Subjects who are investigational site staff members directly involved in the conduct
of the trial and their family members, site staff members otherwise supervised by the
Investigator, or subject who are Pfizer employees directly involved in the conduct of
the trial;
15. Treatment with any investigational product during the last 28 days;
16. QTc > 480ms, QT syndrome, Brugada syndrome, history QTc prolongation or Torsade de
Points;
17. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or may
interfere with the interpretation of study results and, in the judgment of the
investigator, would make the subject inappropriate for entry into this study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Edmonton, Alberta
- Surrey, British Columbia
- Vancouver, British Columbia
- Halifax, Nova Scotia
- Hamilton, Ontario
- London, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Belo Horizonte, Minas Gerais
- Porto Alegre, Rio Grande Do Sul
- Rio De Janeiro,
- São Paulo,
- São Paulo,
- São Paulo,
- São Paulo,
- The Woodlands, Texas
- Costa Masnaga, Lecco
- Tainan City,
- Roanoke, Virginia
- Copenhagen,
- Kagoshima,
- Cleveland, Ohio
- Seoul,
- Orange, California
- Poznan,
- Bedford, Texas
- Graz,
- Kawasaki, Kanagawa
- Piacenza,
- Shelbyville, Tennessee
- Leuven,
- Taoyuan City,
- Pierre Benite cedex,
- Santa Barbara, California
- Philadelphia, Pennsylvania
- Seoul,
- Caen Cedex 5,
- Dublin,
- Velikiy Novgorod,
- Kernersville, North Carolina
- Cremona,
- Nottingham,
- Calgary, Alberta
- Matsuyama, Ehime
- Louisville, Kentucky
- Praha 2,
- Nice cedex 2,
- Fairway, Kansas
- Asheville, North Carolina
- Krakow,
- London,
- Oslo,
- Boston, Massachusetts
- Prato,
- Singapore,
- Wellington, Florida
- Innsbruck,
- Rogers, Arkansas
- Seoul,
- Nottingham,
- Rybnik,
- Brisbane, Queensland
- Bergen,
- Brussels,
- Tucson, Arizona
- Bergamo,
- Mayfield Heights, Ohio
- Bebington, Wirral, Merseyside
- Dublin 7, Dublin
- Scottsdale, Arizona
- Sutton, Surrey
- Moscow,
- Praha 2,
- Austin, Texas
- Atlanta, Georgia
- Seoul,
- Saint Petersburg,
- Kansas City, Missouri
- Boulder, Colorado
- Cremona,
- Winston-Salem, North Carolina
- Rimini,
- Lugo, Ravenna
- Montreal, Quebec
- Olomouc,
- Phoenix, Arizona
- Milwaukee, Wisconsin
- Chermside, Queensland
- Glasgow,
- Tucson, Arizona
- London,
- Zurich,
- Waterford,
- Fort Worth, Texas
- London,
- Irving, Texas
- Bellinzona, Ticino
- London,
- Chuo-ku, Tokyo
- Goyangsi, Gyeonggi-do
- Cordoba,
- Murfreesboro, Tennessee
- Toon, Ehime
- Madrid,
- Lyon cedex 08,
- Cleveland, Ohio
- Parkville, Victoria
- New Lambton Heights, New South Wales
- Miano, Milano
- Basel, Basel-stadt
- Isehara, Kanagawa
- Winnipeg, Manitoba
- Seoul,
- Auchenflower, Queensland
- Seoul,
- Atlanta, Georgia
- Milwaukee, Wisconsin
- Gallatin, Tennessee
- Mayfield Heights, Ohio
- Candiolo, Torino
- Philadelphia, Pennsylvania
- Daytona Beach, Florida
- Cleveland, Ohio
- Praha 2, Czech Republic
- Dublin,
- Parkville, Victoria
- Taipei City,
- Bethesda, Maryland
- Northwood, Middlesex
- Herston, Queensland
- Bunkyo-ku, Tokyo
- Taipei,
- Manerbio, Brescia
- Zurich,
- Yokohama, Kanagawa
- Boston, Massachusetts
- Girona,
- Vandoeuvre-lès-Nancy,
- London,
- Dublin 4,
- Taoyuan City,
- L'Hospitalet de Llobregat, Barcelona
- Seoul,
- Aurora, Colorado
- Asheville, North Carolina
- Prato,
- Boston, Massachusetts
- Kelowna, British Columbia
- Parkville, Victoria
- Louisville, Kentucky
- Madrid,
- Douglasville, Georgia
- Glasgow, CITY OF Glasgow
- Cartersville, Georgia
- Krakow,
- Singapore,
- Daegu,
- Taipei City,
- Westwood, Kansas
- Toronto, Ontario
- Chelyabinsk,
- Austell, Georgia
- Stockport,
- Edmonton, Alberta
- Halifax, Nova Scotia
- Headington, Oxford
- West Palm Beach, Florida
- Winnipeg, Manitoba
- South Brisbane, Queensland
- Halifax, Nova Scotia
- Silver Spring, Maryland
- Hermitage, Tennessee
- Toronto, Ontario
- Tsukuba, Ibaraki
- Hamamatsu, Shizuoka
- Taipei,
- Oslo,
- Luzern 16, Luzern
- Newcastle, New South Wales
- Dickson, Tennessee
- Gent, EAST Flanders
- Herston, Queensland
- Melbourne, Victoria
- Albuquerque, New Mexico
- Namur,
- Nashville, Tennessee
- Taipei city,
- London,
- Dublin 4,
- Piacenza,
- Praha 5,
- Zurich,
- Fayetteville, Arkansas
- Bebington, Wirral, Merseyside
- Silver Spring, Maryland
- Winnipeg, Manitoba
- Pyatigorsk, Stavropol Region
- Taipei City,
- Taipei,
- Hidaka, Saitama
- Brescia,
- Debrecen,
- Paris cedex 15,
- Nashville, Tennessee
- Nizhniy Novgorod,
- Nashville, Tennessee
- Niigata,
- Louisville, Kentucky
- Louisville, Kentucky
- Nashville, Tennessee
- Kortrijk,
- Phoenix, Arizona
- Kita-adachi-gun, Saitama
- Philadelphia, Pennsylvania
- Ottawa, Ontario
- Singapore,
- Maastricht,
- Chelyabinsk,
- Praha 2,
- Aalborg,
- Roanoke, Virginia
- Austin, Texas
- Montreal, Quebec
- Marietta, Georgia
- Torino,
- Milano,
- Dublin,
- Franklin, Tennessee
- Sutton, Surrey
- Poznan,
- Dublin 7, Dublin
- Sapporo, Hokkaido
- Irving, Texas
- Southport, Queensland
- Hong Kong,
- Ostrava-Poruba,
- Malvern, Victoria
- Cleveland, Ohio
- Budapest,
- Manchester,
- Lakewood, Colorado
- Singapore,
- Groningen,
- Lebanon, Tennessee
- Smyrna, Tennessee
- Paris,
- Rybnik,
- Seoul,
- Reno, Nevada
- Nashville, Tennessee
- Zurich,
- South Brisbane, Queensland
- Athens/New Kifissia,
- Debrecen,
- Chandler, Arizona
- Krasnodar,
- Tainan city,
- Atlanta, Georgia
- Auchenflower, Queensland
- Kagoshima,
- Liege,
- Cleveland, Ohio
- Groningen,
- Herston, Queensland
- Jerusalem,
- Tempe, Arizona
- Sochi, Krasnodar Region
- Seoul,
- San Antonio, Texas
- Usti nad Labem,
- Olsztyn,
- Louisville, Kentucky
- Brighton, Victoria
- Orenburg,
- Seoul,
- Sendai, Miyagi
- Salt Lake City, Utah
- Cambridge, Cambridgeshire
- Tokorozawa, Saitama
- Cremona,
- Seoul,
- Bergen,
- Solvang, California
- Montreal, Quebec
- Szolnok,
- Bergamo,
- Albuquerque, New Mexico
- Northampton, Northamptonshire
- Bergamo,
- South Brisbane, Queensland
- Boston, Massachusetts
- Taipei City,
- Olsztyn,
- Madrid,
- Zurich,
- Columbia, Maryland
- Vancouver, British Columbia
- Daegu,
- Shimotsuke, Tochigi
- Basel, Basel-stadt
- Athens,
- Eugene, Oregon
- Hong Kong,
- Villejuif cedex,
- Akashi, Hyogo
- Carrollton, Georgia
- Louisville, Kentucky
- Budapest,
- Leiden,
- Singapore,
- Louisville, Kentucky
- Sevilla,
- Como,
- Chandler, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Scottsdale, Arizona
- Tempe, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Fayetteville, Arkansas
- Rogers, Arkansas
- Orange, California
- Santa Barbara, California
- Solvang, California
- Aurora, Colorado
- Boulder, Colorado
- Lakewood, Colorado
- Daytona Beach, Florida
- Wellington, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Austell, Georgia
- Carrollton, Georgia
- Cartersville, Georgia
- Douglasville, Georgia
- Marietta, Georgia
- Fairway, Kansas
- Westwood, Kansas
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Bethesda, Maryland
- Columbia, Maryland
- Silver Spring, Maryland
- Silver Spring, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Kansas City, Missouri
- Reno, Nevada
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- Asheville, North Carolina
- Asheville, North Carolina
- Kernersville, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Mayfield Heights, Ohio
- Mayfield Heights, Ohio
- Eugene, Oregon
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Dickson, Tennessee
- Franklin, Tennessee
- Gallatin, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Shelbyville, Tennessee
- Smyrna, Tennessee
- Austin, Texas
- Austin, Texas
- Bedford, Texas
- Fort Worth, Texas
- Irving, Texas
- Irving, Texas
- San Antonio, Texas
- The Woodlands, Texas
- Salt Lake City, Utah
- Roanoke, Virginia
- Roanoke, Virginia
- Milwaukee, Wisconsin
- Milwaukee, Wisconsin
- New Lambton Heights, New South Wales
- Newcastle, New South Wales
- Auchenflower, Queensland
- Auchenflower, Queensland
- Brisbane, Queensland
- Chermside, Queensland
- Herston, Queensland
- Herston, Queensland
- Herston, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- Southport, Queensland
- Brighton, Victoria
- Malvern, Victoria
- Melbourne, Victoria
- Parkville, Victoria
- Parkville, Victoria
- Parkville, Victoria
- Graz,
- Innsbruck,
- Gent, EAST Flanders
- Brussels,
- Kortrijk,
- Leuven,
- Liege,
- Namur,
- Calgary, Alberta
- Edmonton, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- Halifax, Nova Scotia
- Ottawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Praha 2, Czech Republic
- Olomouc,
- Ostrava-Poruba,
- Praha 2,
- Praha 2,
- Praha 2,
- Praha 5,
- Usti nad Labem,
- Aalborg,
- Copenhagen,
- Caen Cedex 5,
- Lyon cedex 08,
- LYON cedex 8,
- Nice cedex 2,
- Paris cedex 15,
- Paris,
- Pierre Benite cedex,
- Vandoeuvre-lès-Nancy,
- Villejuif cedex,
- Athens/New Kifissia,
- Athens,
- Hong Kong,
- Hong Kong,
- Budapest,
- Budapest,
- Debrecen,
- Debrecen,
- Szolnok,
- Dublin 7, Dublin
- Dublin 7, Dublin
- Dublin 4,
- Dublin 4,
- Dublin,
- Dublin,
- Dublin,
- Waterford,
- Jerusalem,
- Manerbio, Brescia
- Costa Masnaga, Lecco
- Miano, Milano
- Lugo, Ravenna
- Candiolo, Torino
- Bergamo,
- Bergamo,
- Bergamo,
- Brescia,
- Como,
- Cremona,
- Cremona,
- Cremona,
- Milano,
- Piacenza,
- Piacenza,
- Prato,
- Prato,
- Rimini,
- Torino,
- Matsuyama, Ehime
- Toon, Ehime
- Sapporo, Hokkaido
- Akashi, Hyogo
- Tsukuba, Ibaraki
- Isehara, Kanagawa
- Kawasaki, Kanagawa
- Yokohama, Kanagawa
- Sendai, Miyagi
- Hidaka, Saitama
- Kita-adachi-gun, Saitama
- Tokorozawa, Saitama
- Hamamatsu, Shizuoka
- Shimotsuke, Tochigi
- Bunkyo-ku, Tokyo
- Chuo-ku, Tokyo
- Kagoshima,
- Kagoshima,
- Niigata,
- Goyangsi, Gyeonggi-do
- Daegu,
- Daegu,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Groningen,
- Groningen,
- Leiden,
- Maastricht,
- Bergen,
- Bergen,
- Oslo,
- Oslo,
- Krakow,
- Krakow,
- Olsztyn,
- Olsztyn,
- Poznan,
- Poznan,
- Rybnik,
- Rybnik,
- Sochi, Krasnodar Region
- Pyatigorsk, Stavropol Region
- Chelyabinsk,
- Chelyabinsk,
- Krasnodar,
- Moscow,
- Nizhniy Novgorod,
- Orenburg,
- Saint Petersburg,
- Velikiy Novgorod,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
- L'Hospitalet de Llobregat, Barcelona
- Cordoba,
- Girona,
- Madrid,
- Madrid,
- Madrid,
- Sevilla,
- Basel, Basel-stadt
- Basel, Basel-stadt
- Luzern 16, Luzern
- Bellinzona, Ticino
- Zurich,
- Zurich,
- Zurich,
- Zurich,
- Zurich,
- Tainan city,
- Tainan City,
- Taipei city,
- Taipei City,
- Taipei City,
- Taipei City,
- Taipei City,
- Taipei,
- Taipei,
- Taipei,
- Taoyuan City,
- Taoyuan City,
- Cambridge, Cambridgeshire
- Glasgow, CITY OF Glasgow
- Bebington, Wirral, Merseyside
- Bebington, Wirral, Merseyside
- Northwood, Middlesex
- Northampton, Northamptonshire
- Headington, Oxford
- Sutton, Surrey
- Sutton, Surrey
- Glasgow,
- London,
- London,
- London,
- London,
- London,
- London,
- Manchester,
- Nottingham,
- Nottingham,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer. | ||||||
Official Title ICMJE | Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer. | ||||||
Brief Summary | The primary objective of this study is to evaluate 12 weeks progression-free survival (PFS) rate of Palbociclib plus Letrozole in ER/PR positive endometrioid or high-grade serous ovarian cancer who have disease progression on second-line chemotherapy. | ||||||
Detailed Description | Letrozole (Femara®) is an oral non-steroidal aromatase inhibitor that is approved worldwide for the treatment of postmenopausal women with breast cancer. It is administered orally on a continuous 2.5 mg daily dosing regimen and has a good toxicity profile. Palbociclib (Ibrance®) is an active potent and highly selective reversible inhibitor of cyclin- dependent kinases 4 and 6 (CDK4/6). Palbociclib was approved by the United States Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor based on a randomized, double-blind, placebo-controlled, international clinical trial PALOMA-2. It is administered orally on a dose of 125 mg per day in 4-week cycles (3 weeks of treatment followed by 1 week off). This trial was based on preclinical studies that showed a synergistic effect between targeting the ER and cyclin-D-CDK4/6-Rb pathway. The principal toxicity was myelotoxicity but it was managed with appropriate supportive care and dose reductions13. Based on the results of phase 1 and 2 clinical trials of CDK4/6 inhibitors used as monotherapy to treat patients with recurrent ovarian cancer, we hypothesized that, as Palbociclibe is active in this population and many ovarian cancer show ER/PR expression, its combination with Letrozole can improve outcomes in ER/PR positive endometrioid or high-grade serous Ovarian Cancer who have disease progression on second-line chemotherapy, similar to what is seen in breast cancer studies. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE | Ovarian Cancer | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE | Experimental: Palbociclib 125mg + Letrozole 2.5mg
Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment). Interventions:
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 39 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | March 4, 2023 | ||||||
Estimated Primary Completion Date | April 4, 2021 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Brazil | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03936270 | ||||||
Other Study ID Numbers ICMJE | LACOG 1018 | ||||||
Has Data Monitoring Committee | Not Provided | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Latin American Cooperative Oncology Group | ||||||
Study Sponsor ICMJE | Latin American Cooperative Oncology Group | ||||||
Collaborators ICMJE | Pfizer | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Latin American Cooperative Oncology Group | ||||||
Verification Date | December 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |